⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15534022 | 0.82 | — | — | |
| SCHEMBL23067807 | 0.82 | — | — | |
| SCHEMBL11971122 | 0.79 | — | — | |
| SCHEMBL129130 | 0.75 | ALDH1A1 (0.39) | — | |
| SCHEMBL130330 | 0.75 | ALDH1A1 (0.33) | — | |
| SCHEMBL25045767 | 0.75 | — | — | |
| SCHEMBL17621626 | 0.74 | — | — | |
| SCHEMBL24814669 | 0.73 | — | — | |
| SCHEMBL16569757 | 0.73 | — | — | |
| SCHEMBL16714 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743447-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743178-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025016909-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025016906-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-23 | — | — | WO | disclosed |
| CN-118852154-A | Carboxamide substituted hetero tricyclic derivative, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3186239-A1 | ANTIRETROVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016033243-A1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9212175-B2 | Pharmaceutical hypocholesterolemic compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-9212175-B2 | Pharmaceutical hypocholesterolemic compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20120065168-A1 | Pharmaceutical Hypocholesterolemic Compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2012-03-15 | — | — | US | disclosed |